CXCL12 and myeloid sarcoma: To know whether this phenotypic change was associated with the modulation of plasmaticcytokines/chemokines concentrations, we seek for differences in sIL2RA, IL-15, CXCL10, CCL2, CCL20,and CXCL12 plasmatic content between MS patients with CD206hi CD209hi Mo and MS patients without CD206hi CD209hi Mo.